Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
23 hedge funds and large institutions have $1.66M invested in Carisma Therapeutics in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
21% less funds holding
Funds holding: 29 → 23 (-6)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
95% less capital invested
Capital invested by funds: $33.7M → $1.66M (-$32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$705K |
| 2 |
Renaissance Technologies
New York
|
+$77.8K |
| 3 |
Goldman Sachs
New York
|
+$21.6K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$16.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$9.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.62M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$6.97M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$2.64M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.33M |
| 5 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$338K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$44K | -737 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$1K | -22 | Closed |
|
28
Morgan Stanley
New York
| – | -$69 | -5 | -33% |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$69 | -5 | -17% |
|
30
Citigroup
New York
| – | +$41 | +3 | +10% |
|
CARM Hedge Fund Activity: Q1 2016 in Review
23 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2016, worth a combined $1.66M — down 95% from $33.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CARM and 5 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Sabby Management, adding an estimated $705K. The largest seller was Fidelity Investments, exiting entirely with an estimated $8.62M sold.
- 23 institutional investors held Carisma Therapeutics (CARM) as of Q1 2016, down from 29 in Q4 2015.
- Funds reported $1.66M of Carisma Therapeutics stock for Q1 2016, down 95% quarter-over-quarter.
- 5 funds opened new Carisma Therapeutics positions in Q1 2016 and 9 closed out, a net change of -4 holders.
- The largest Carisma Therapeutics buyer in Q1 2016 was Sabby Management, an estimated $705K added.
- The largest Carisma Therapeutics seller in Q1 2016 was Fidelity Investments, an estimated $8.62M sold.
Based on aggregated 13F filings for Q1 2016.